4月25日,国家药品监督管理局(NMPA)官网显示,康方生物的依沃西单抗注射液新适应症上市申请已获批准,用于单药一线治疗PD-L1表达阳性(PD-L1 TPS≥1%)的局部晚期或转移性非小细胞肺癌。此次依沃西新适应症上市申请是基于HARMONi-2(AK112-303)研究。HARMONi-2研究的期中分析已经取得了强阳性结果:在意向治疗人群(ITT)中,依沃西单抗单药相较于帕博利珠单抗单药显著...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.